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Technology for the derivation, propagation, and characterization of pluripotent stem cell lines from the
human embryo has undergone considerable refinement and improvement since the first published descrip-
tion of human embryonic stem cells in 1998. In particular, there has been extensive effort to optimize proto-
cols and develop defined culture systems with a view toward future clinical applications of embryonic stem
cell-derived products. Here, we review the current status of methodology for human embryonic stem cell
derivation and culture, and we highlight the challenges that remain for workers in the field.Introduction
Today the derivation of new pluripotent stem cell lines from
human embryos continues to be a highly active area of research,
for several reasons. First, the technology for derivation and prop-
agation of pluripotent human stem cell lines is constantly being
refined and improved, providing opportunities to optimize devel-
opment of cell lines for clinical use. Second, cell therapies based
on human embryonic stem cells (hESCs) are likely to enter clin-
ical trial very soon. It is predictable that the lessons learned
from the first trials will drive further refinement of stem cell tech-
nology, and that as clinical work progresses, wider panels of cell
lines will be required for particular applications and for tissue
matching. Third, changes to policy for US Federal funding of
embryonic stem cell research now allow workers there to study
a much larger range of cell lines than was previously possible.
Finally, despite the remarkable discovery of adult cell reprog-
ramming to the pluripotent state (induced pluripotent stem cells
[iPSCs]), continued uncertainty about the bioequivelance of
human ESCs and hiPSCs suggests that hESCs will remain the
gold standard for research and therapy for the near to mid-
term future.
Here, we review the current status of human ESC line deriva-
tion. We consider the rationale for generation of new cell lines,
the technologies available now for their derivation and propaga-
tion, and thecurrent standards for their characterization (Figure1).
Scientific Justification and Ethical Criteria
for New Derivations
Any efforts to derive new hESC lines should be justified scientif-
ically. A recent analysis of the literature indicated that there are
now over 1000 hESC lines in existence and that 70% of these
have been characterized to some degree in peer-reviewed publi-
cations (Lo¨ser et al., 2010). However, much of the scientific liter-
ature on hESC is based on only a handful of cell lines (McCor-
mick et al., 2009; Scott et al., 2009). Given that there are over
a thousand hESC lines in existence, there is certainly a case
for more work on a wider range of these established cell lines
(assuming that the majority are in fact available for distribution).However, what scientific rationale justify generation of additional
cell lines?
First, genetic or epigenetic variation in the ability of hESC lines
to undergo differentiation into particular lineages remains
a largely unknown factor. Thus it is uncertain howmany cell lines
might be required to provide a panel with, for example, high
competency for beta islet cell formation. Similarly, little is known
about how genetic or epigenetic stability varies between
different hESC lines. Second, estimates of the number of hESC
lines that will be required to provide adequate coverage for
tissue matching in transplantation vary. Limited studies suggest
that existing cell lines are not representative of a wide range of
ethnic diversity (Laurent et al., 2010 ; Mosher et al., 2010), and
the problem of matching populations of mixed racial origin has
not really been addressed. Third, only a small minority of the
published cell lines have been derived under conditions that
are optimal for future clinical use. Technology for hESC deriva-
tion, maintenance, and expansion are constantly evolving, and
there is a strong argument for deriving cell lines with improved
methodology.
Although the advent of iPSC technology may circumvent
ethical roadblocks around the use of embryos in research, there
are still questions over the biological equivalence and safety of
iPSC lines compared to hESC (Lee et al., 2009). Some concerns
include limitations or reductions in developmental potential (Hu
et al., 2010; Kim et al., 2010), variability relating to the starting
cell type used for reprogramming (Kulkeaw et al., 2010), and
an epigenetic/gene expression profile that may suggest an inde-
pendent pluripotent state for iPSCs when compared to ESCs
(Doi et al., 2009; Chin et al., 2009). hESCs, as such, remain the
standard by which all other pluripotent cell lines are judged
(Hyun et al., 2007; Smith et al., 2009).
The research community has been moving toward uniform
international ethical standards for the derivation of new cell lines.
The European Union started the process in 2004 with Directive
2004/23/EC, the International Society for Stem Cell Research
(ISSCR) followed in 2007, and the National Institutes of Health
(NIH) followed in 2009. Each of these sets of guidelines, sub-
jected to public comment and extensive refinement, adheresCell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc. 521
Table 1. Common Principles Shared across hESC Derivation
Guidelines
Only unused embryos created for the purpose of in vitro fertilization
(IVF) should be used for the derivation of ESCs.
Donors should voluntarily consent to the donation of embryos for
research without influence from those participating in the study.
The standard of IVF care should be unaffected by the decision to
donate.
No financial compensation was made for the donation.
Donors should be informed of alternatives to donation, that embryos
would be used for the derivation of ESCs, that no direct medical
benefit was intended, that the ESCs may have commercial potential
to which they would not be entitled, that identifying information would
remain confidential, and that they may withdraw from the study until
the embryos are actually used.
Figure 1. Schematic of the Process of Human Embryonic Stem Cell
Line Establishment
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ethical standards in the study of hESCs (Table 1). The push to
implement these standards is reflected in the European Human
Embryonic StemCell Registry (hESCreg) and the NIH Embryonic
Stem Cell Registry. The NIH registry currently comprises 64 lines
that adhere to US federal guidelines with 12 more in submission
as of May 2010. Although hESCreg has over 650 lines listed, the
provenance of only a small fraction has been validated to meet
European/international guidelines.
As hESC technology moves into the translational and clinical
stage, standards for derivation of cell lines will become more
stringent. The first step toward the clinic involves the derivation
and characterization of Good Manufacturing Practice (GMP)
quality cell lines (A¨hrlund-Richter et al., 2009). In order to qualify
for GMP, the cell lines must be derived and cultured in: (1)
defined and (2) controlled conditions (3) by trained staff (4) with
full documentation. Some proprietary lines have been derived
under GMP conditions (ESI, WiCell), and only one cell line, H1,
has been maintained under GMP conditions and approved for
clinical trials (Geron Corporation). It should be noted that GMP
does not preclude the use of products derived from animal sour-
ces, such as fetal calf serum, so long as the product meets the
GMP standards defined above and no other suitable products522 Cell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc.are available. Future clinical acceptance of any new hESC line,
however, can only be improved by the combination of xeno-
free GMP methods for derivation and maintenance.
Human Embryo Culture, Assessment,
and Establishment of hESCs
Embryo Culture and Assessment
Figure 1 illustrates some key phases in the life history of a hESC
line, beginning with embryo culture. Human embryo culture has
been refined over the 30+ years since the first successful in vitro
fertilization (IVF) procedure. In general, procedures for culture of
the fertilized egg from the two pronuclear (2PN) stage of fertiliza-
tion through initial cleavage and transfer to the uterus for implan-
tation have sought to mimic the conditions that a zygote would
experience while traveling through the fallopian tube. Human
tubal fluid nearest the ovary is high in pyruvate and lactate,
whereas the concentration of glucose increases as the zygote
nears the uterus. Therefore, it is common to culture human
embryos in sequential media wherein a human tubal fluid analog
medium is used from fertilization to the eight-cell stage at day 3,
and this is followed by a switch to a high glucose, complete
medium for compaction and blastocyst formation on days 5–6
(Bongso and Tan 2005;Mercader et al., 2006; Ilic et al., 2007; Sa-
thananthan and Osianlis, 2010). However, some workers argue
that a single-media system yields equivalent results (Biggers
and Summers, 2008). Many embryo culture protocols have em-
ployed coculture systems using fibroblasts, endometrial cells, or
other cell types to support development, and a recent meta-
analysis indicated that coculture does indeed improve embryo
quality (Kattal et al., 2008). However, coculture of embryos has
the same drawbacks as the use of feeder cells during establish-
ment and maintenance.
Embryo quality is a critical factor in hESC derivation. For the
most part, assessment of embryo quality continues to rely on
morphological criteria (Bongso and Tan, 2005), although me-
tabolomics (Botros et al., 2008) and proteomics (Katz-Jaffe
et al., 2009) may ultimately provide more objective and accu-
rate evaluation. The highest level of success comes from
implantation of high-quality, expanded blastocysts on day
5/6 (Figure 2 A), and reported success in hESC derivation is
also greatest under these parameters. Because the best avail-
able embryos are of course used for transfer to the uterus,
Figure 2. hESC Colonies Derived and Cultured under
Various Conditions
Full grown day 6 human blastocyst (A) and isolated ICM (B). (C)
shows an attached ICM with growing pluripotent cells, 1
day after seeding on feeder layer. Morphologies of hESC colo-
nies growing in KSR medium on conventional MEF feeder-
layer (D), in KSR medium on human dermal fibroblast
feeder-layer (E), in KSRmedium on xeno-free prepared human
dermal fibroblast feeder-layer (F), in xeno-and feeder-free
medium mTesR2 (G). (A)–(C) are courtesy of Dr Suemori and
were generated according to the methods published in
Suemori et al. (2006).
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highest quality. Several groups (Mitalipova et al., 2003) have
reported derivation of ESC lines from poor-quality embryos,
and a recent study confirmed the potential of this approach
(Lerou et al., 2008), although success rates were quite low
unless the embryos were able to reach the blastocyst stage.
Timing of inner cell mass (ICM) isolation is another critical
factor determining the outcome of derivation. Most of hESC
lines have been derived from blastocysts at day 5/6 of culture.
A recent study indicated up to 50% efficiency when blasto-
cysts were allowed to develop until day 6 (Chen et al., 2009).
At this stage, the isolated ICM attaches to the feeder layer
with relative ease and starts proliferating (Figures 2B and
2C). These results are reflective of the higher rates of success-
ful implantation during IVF treatment when blastocyst stage
embryos are used.
Avoiding Immunosurgery and Exposure
to Animal Products
Although some workers have derived hESCs from explanted
blastocysts, most have relied on immunosurgery for isolation
of the ICM (Figure 2B) (Solter and Knowles, 1975; Bongso
et al., 1994). Because trophectoderm cells show rapid rates
of growth and may inhibit the expansion of the ICM in culture,
their early removal is considered beneficial by most workers.
Immunosurgery requires the use of xenomaterials in the form
of animal-sourced antibodies and complement. Whole and
partial-embryo culture methods (Kim et al., 2005) can eliminate
the need for immunosurgery, but do not enrich for ICM during
initial derivation. Two alternate approaches avoid the pitfalls ofCimmunosurgery with animal components and
whole-embryo culture. First, the ICM can be iso-
lated mechanically by dissection with sharpened
metal needles (Stro¨m et al., 2007). The second
possibility is to perform the isolation with infrared
lasers, which are widely used for drilling holes in
the zona pelucida of eggs and early embryos for
preimplantation genetic diagnosis (PGD) testing.
The infrared laser can be used to isolate the
ICM through ablation of the zona pelucida and
trophectoderm (Turetsky et al., 2008). Proof of
concept of this technique was demonstrated on
genetically abnormal embryos identified during
PGD, with three out of eight ICMs producing
disease-specific hESC lines. A more recent
study using laser-assisted derivation in human
embryos reported derivation efficiency as highas 52% when isolating ICMs from day 6 blastocysts (Chen
et al., 2009).
Blastomere Culture
Several groups have examined the potential for hESC derivation
from single blastomeres. Given that PGD entails biopsy of
a single blastomere and allows for the normal development of
the remaining cleavage-stage embryo, blastomere biopsies
were undertaken to create new hESCs without the destruction
of embryos, to avoid ethical concerns. The technique was first
reported in the mouse in 2006 (Chung et al., 2006), and this
report was closely followed by the derivation of hESCs from
human blastomeres (Klimanskaya et al., 2006). Coculture of
the blastomere with existing hESC cell lines was a necessity in
these studies, a potential limitation to the use of the technique
for deriving clinical grade lines. Another study employed cocul-
ture with the parent embryo with some success (Chung et al.,
2008). This method of coculture with the parent embryo also
produced blastomere derived hESCs in the presence of human
feeders andminimal xenomaterials (Ilic et al., 2009). It is possible
that maintaining the parent embryo in culture with the biopsied
blastomere may restrict its future use in IVF treatment, so elimi-
nation of this step is important. In 2009 a group used four-cell
stage embryos and isolated individual blastomeres (Geens
et al., 2009). Each blastomere was allowed to develop in sequen-
tial medium until day 3 or 4 when they were transferred to inacti-
vated MEFs. Two new cell lines were established, only one of
which was karyotypically normal.
Derivation of hESCs from blastomeres represents an inter-
esting technical achievement, and the technique has theell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc. 523
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derived from presumed totipotent blastomeres of early stages
versus pluripotent cells derived from the later-stage ICM of the
blastocyst. Although it has been argued that such an approach
can leave a viable embryo intact (on the basis of experience
with preimplantation genetic diagnosis) and thus circumvent
ethical issues around embryo destruction, it seems unlikely
that clinicians would chose to implant an embryo that had under-
gone biopsy in preference to one that had not (unless there were
a clinical indication for carrying out the biopsy). Therefore, it is
unclear whether such procedures would ultimately impact on
the long-term viability of the embryos, which would likely be dis-
carded anyway.
Culture Methodology for hESCs
This section, and the following one on cell characterization,
focuses on methodologies developed for hESCs. Although
a detailed discussion of the generation, maintenance and char-
acterization of iPSCs is beyond the scope of this review, it is
worth noting that the same culture systems used to propagate
hESCs have been used in the establishment and expansion of
human iPSCs. There is as yet no evidence that hESCs and iPSCs
differ in terms of the extrinsic signaling mechanisms that control
their growth and differentiation, although the question has not
been systematically investigated. Arguably, human iPSC devel-
opment would not have been possible without previous studies
of hESC culture methodology, the requirements of which are of
course different to those of mouse ESC culture.
Culture Media
Originally, hESCs were established and cultured in medium sup-
plemented with 10%–20% fetal calf serum (FCS) on mouse
embryonic fibroblast (MEF) feeder layers (Reubinoff et al.,
2000; Thomson et al., 1998). Currently, themost common culture
system in research use of hESCs is based on supplementation
with knockout serum replacement (KSR) and 4–10 ng/ml FGF2,
using either MEF feeder cell layers or feeder cell-conditioned
medium (Amit et al., 2000) (Figure 2D). This platform includes
xenomaterials, a significant drawback for clinical use because
of the potential for transmission of pathogens. Therefore, several
media containing human serum (or serum components) instead
of FCS and human feeder layers instead of MEF have been
developed for establishment and maintenance of clinical-grade
hESCs (Crook et al., 2007; Ellerstro¨m et al., 2006; Rajala et al.,
2007) (Figure 2E). Recently, xeno-free serum replacements,
such as xeno-free KSR (Invitrogen), or xeno-free culture
medium, such as HESGRO (Millipore) have become commer-
cially available and enable themaintenance of hESCs in an undif-
ferentiated state in feeder cell culture systems (Figure 2F).
Notably, undifferentiated hESCs retain slightly different morphol-
ogies in different culture systems.
hESC culture on a feeder cell layer introduces another source
of possible contamination by adventitious agents. Feeder cell
layers can produce proteins and small molecules that interfere
with studies of stem cell maintenance and differentiation factors
in unpredictable ways. In addition, a human feeder layer may
introduce ambiguity in any subsequent genetic analysis. There-
fore, the development of xeno-free and feeder-free, fully defined
systems for establishment and culture of hESCs had been a goal
in this field for some time. The first attempts to eliminate the524 Cell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc.feeder cell component from hESC culture used MEF-condi-
tioned medium (Xu et al., 2001), which of course still carries
the same risk of contamination with adventitious agents as
feeder cell culture. The elucidation of the key signaling pathways
for hESC self-renewal has enabled replacement of any require-
ment for feeder cells or their secreted products. In contrast to
mESCs, hESCs do not appear to require LIF/STAT3 or BMP
signaling for self-renewal (Dahe´ron et al., 2004; Humphrey
et al., 2004; Xu et al., 2002). However, activation of signaling
by receptor tyrosine kinases, in particular by FGF2 (Eiselleova
et al., 2009; Gonzalez et al., 2010), IGF/insulin (Bendall et al.,
2007; Levenstein et al., 2008; Li et al., 2007), and sphingosine-
1-phosphate/ PDGF (Wong et al., 2007), upstream of ERK and
PI3K/AKT (Armstrong et al., 2006; Li et al., 2007; Soh et al.,
2007) and in combination with TGF-ß/Activin/ Nodal/activation
of SMAD 2/3 (Amit et al., 2004; Vallier et al., 2005; Vallier et al.,
2009; Xiao et al., 2006), appears to be critical for hESC mainte-
nance. Other studies have implicated WNT/ b-catenin (Dravid
et al., 2005; Lu et al., 2006; Sato et al., 2004), and TNF receptor
superfamilies in hESC survival (Lu et al., 2006). Inhibition of BMP
signaling can prevent spontaneous differentiation (Pera et al.,
2004; Xu et al., 2005). On the basis of these findings, many
feeder-free, xeno-free defined culture media consisting of
combinations of recombinant growth factors activating stem
cell maintenance pathways or inhibiting differentiation have
been reported (Li et al., 2005; Liu et al., 2006; Ludwig et al.,
2006; Peiffer et al., 2010; Swistowski et al., 2009; Wagner and
Vemuri, 2010; Yao et al., 2006). Notably, the use of these defined
media often requires a process of culture adaptation; hESC may
become unstable for a few passages after transfer from feeder
cell culture conditions (Akopian et al., 2010). Some of the xeno-
free and feeder-free defined culturemedia are now commercially
available, such as mTeSR2 (StemCell Technologies), StemPro
(Invitrogen), SBX (AxCell), NutriStem (Stemgent), and VitroHES
(Vitrolife). hESCs can be expanded and maintained in the undif-
ferentiated state in these media (Figure 2G). However, only
TeSR1, a noncommercially available analog of mTeSR2, has
been reported to support establishment of hESC lines from blas-
tocysts (Ludwig et al., 2006).
Given that all recombinant or purified growth factors are
costly, many groups have used hESCs in high-throughput
screening system to identify small molecules capable of sup-
porting stem cell maintenance (Damoiseaux et al., 2009;
Desbordes et al., 2008; Lin et al., 2009). It was reported that
a combination of a histone deacetylase (HDAC) inhibitor and
an inhibitor of GSK3b could maintain hESCs in the undifferenti-
ated state (Sato et al., 2004; Ware et al., 2009). Recently,
a small-molecule BMP receptor type 1 (BMPR-I)-specific inhib-
itor LDN-193189 that might inhibit spontaneous differentiation
in hESC culture was identified through chemical screening
(Yu et al., 2008). It was also recently reported that the combined
use of a MEK/ERK inhibitor and Activin inhibitor could improve
human iPSC induction (Lin et al., 2009), although given thewidely
recognized role for these pathways in hESC maintenance, the
mechanism of this effect requires further study.
One report has suggested that feeder-free culture is associ-
atedwithmore chromosomal instability than conventional feeder
cell based systems (Catalina et al., 2008). Therefore, feeder-free
culture systems may require more frequent karyotypic
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tions favor maintenance of a normal karyotype. Several reports
have demonstrated that low oxygen tension could reduce chro-
mosomal abnormalities and also prevent hESC differentiation
(Ezashi et al., 2005; Forsyth et al., 2006). A very recent study
showed that a small molecule selectively inhibits growth of chro-
mosomally abnormal hESCs and cancer cells, but not normal
hESCs (Gauthaman et al., 2009). This report requires further
confirmation, but this or related strategies might be necessary
to reduce the risk of generating and propagating abnormal cells
in defined culture systems.
Given the limited published success with establishment of
hESC lines in xeno-free/feeder-free medium, it seems realistic
that at present the most reliable strategies for establishment of
clinical grade hESC lines include use of a human feeder cell layer
in xeno-free medium, followed by expansion in a feeder-free
culture system. In general, hESC cultures show a significant
amount of cell death and spontaneous differentiation, which
can be minimized by daily medium exchange and passage
before the culture becomes over grown. Growth rates of hESC
cell lines vary (Cowan et al., 2004) and careful adjustment of
the starting size of the clumps used to seed new dishes at
subculture, colony density, split ratio, and passage interval are
essential. Suboptimal conditions may necessitate removal of
differentiated cells during passage (Ludwig and Thomson, 2007).
Passage Methodology
Initially, hESCs were passaged by mechanical dissociation of
mature colonies into cell clumps with sharpened glass or steel
needles (Reubinoff et al., 2000; Thomson et al., 1998). In the
process of establishment of hESC lines from ICM, differentiated
cells, which may represent extra embryonic lineages, frequently
appear within a colony of undifferentiated cells. Mechanical
dissection produces clumps of an appropriate size for passage
and enables elimination of differentiated cells. The simplest
mechanical passage method is dissection of colonies into
uniform size clumps with a sharp needle (Cowan et al., 2004).
After establishment of hESC lines, large numbers of cells are
required for quality assurance and establishment of cell banks.
Despite considerable efforts to identify factors that improve
cell viability, hESCs survival remains very low after complete
dissociation into single cells, and continuous complete dissoci-
ation may lead to selection of chromosomal abnormal cells
that are capable of survival under these conditions (Hasegawa
et al., 2006). Therefore mechanical, enzymatic, or chemical
dissociation of colonies into 50- to 1000-cell clumps remains
the most common passage method for expansion of hESC
culture. Mechanical dissection is not amenable to scale up or
rapid expansion. Recently, a specialized roller cutting device
for mechanical hESC passage has become commercially avail-
able (EZ passage tool, Invitrogen) (Wagner and Vemuri, 2010),
and such a device might facilitate rapid dissection of a large
number of colonies into uniform size clumps. To further speed
and standardize the process and minimize operator contact,
some workers have used laser dissection of hESC colonies
(Terstegge et al., 2009).
For enzymatic dissociation, collagenase IV, dispase, or
combinations of these and other proteolytic enzymes are
commonly used to detach and dissociate hESCs colonies into
clumps. This procedure requires some experience to produceclumps of the appropriate size for subculture. Many of these
enzymes are derived from animal products. More recently
commercially available xeno-free enzymes (Accutase, Innova-
tive Cell Technologies, or TrypLE, Invitrogen) have been used
to dissociate hESCs to single cells and are reported to provide
higher cell survival after passage (Bajpai et al., 2008; Ellerstro¨m
et al., 2010). These productsmay prove to be useful in expansion
of cell lines. The small molecule Rho-associated kinase (ROCK)
inhibitor Y-27632 or a combination of ROCK inhibitor and protein
kinase C inhibitor have been shown to enhance hESC survival
after passage as single cells (Damoiseaux et al., 2009;Watanabe
et al., 2007). Another report suggested the ROCK inhibitor-medi-
ated cell-cell interaction was associated with cell surface E-
cadherin stabilization (Xu et al., 2010). In this report, it was also
suggested that enhanced integrin signaling synergizes with
growth factors to enhance hESC survival (Xu et al., 2010).
Nonenzymatic dissociation of hESC can also be achieved by
chelation of calcium and magnesium with EDTA (Ludwig and
Thomson, 2007). Either enzymatic or chemical dissociation
may carry a higher risk of induction of chromosomal abnormali-
ties than mechanical colony dissection (Mitalipova et al., 2005)
(Catalina et al., 2008), possibly because either technique can
release single cells. Many of the common chromosomal abnor-
malities seen in cultured hESCs provide a survival advantage,
and dissociation to single cells is a selective pressure, favoring
expansion of abnormal clones.
To date, no approach has provided for high survival of single
hESCs after subculture. Current best practice would probably
utilize mechanical dissection for establishment andmaintenance
of hESCs and either enzymatic or chemical harvest, with care to
avoid dissociation to single cells, for expansion of hESCs over
a limited number of passages.
Several studies describe scale-up of hESC cultures in small
bioreactors (Fong et al., 2005; Krawetz et al., 2009), microcar-
rier-based suspension culture (Oh et al., 2009; Phillips et al.,
2008), or an automated culture system (Terstegge et al., 2007;
Thomas et al., 2009). Steiner et al. (2010) recently described
the derivation of hESCs in a suspension culture system using
basal medium extensively supplemented with a serum replace-
ment including beta D-xylopyranose, growth factors (Activin A,
FGF2 and neurotrophic factors), and extracellular matrix mole-
cules (laminin, fibronectin, and gelatin). hESCs could be
expanded and maintained in this system, although cell produc-
tion was lower relative to monolayer culture on feeder cells due
to increased cell loss, and questions remain over long-term
genetic stability in cultures grown with this technique. Although
experience to date with these scaled-up culture systems is
limited, they may provide a future option for rapid expansion of
hESCs.
Feeder Cells
Although several commercial, defined media are now available
for feeder-free propagation of hESCs, there is only limited expe-
rience with the use of these preparations in derivation of cell
lines. Therefore, many groups continue to use feeder cells in
establishment of hESC lines. The original methodology for
hESC derivation used MEF feeder cells. Subsequently, several
groups reported the use of human fibroblasts as feeder cells,
including cells derived from fetal, neonatal, and adult tissues
(Unger et al., 2008). Cell lines have been derived under GMPCell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc. 525
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fibroblast-like cells derived from hESC culture have been shown
to support hESC growth (Stojkovic et al., 2005), through a para-
crine mechanism (Bendall et al., 2007).
More recently, several groups have shown that extracellular
matrix from human fibroblasts can support hESC maintenance,
either with the use of conditioned medium from the feeder cells
or without it (Escobedo-Lucea and Stojkovic, 2010; Meng
et al., 2010a). In both studies, the fibroblasts were grown in
medium containing human serum. These and related culture
systems, though xeno free, nevertheless are still undefined.
Extracellular Matrix
Derivation of new cell lines in fully defined conditions will require
provision of a natural or synthetic extracellular matrix capable of
supporting hESC attachment survival and growth. As discussed
above, single hESC do not survive in suspension, and even
suspension cultures of cell clumps require supplementation
with extracellular matrix or extracellular matrix addition to micro-
carriers. Most studies have employed serum, Matrigel (BD
Biosciences), or extracellular matrix deposited by the feeder
cell layer to support adhesion, spreading, and growth of hESCs.
None of these systems provides for fully defined culture condi-
tions and many contain animal-derived products. The definition
of the active components in these complex biological prepara-
tions might help in designing a more defined system. The major
attachment factors in serum are fibronectin and vitronectin. Ma-
trigel is a commercial extract of natural basement membrane
that contains laminin, collagen type IV (Braam et al., 2008), en-
tactin, and heparan sulfate proteoglycans. Feeder cells secrete
fibronectin, collagen types I and IV, and laminin. Finally, hESCs
themselves synthesize laminin 511 and nidogen 1 (Evseenko
et al., 2009), and differentiated derivatives in the cultures are
likely to synthesize other matrix components. This information,
alongside analysis of integrin expression in stem cell cultures,
provides a rational basis for the use of defined natural or
recombinant extracellular matrix components to support hESC
growth and derivation. hESCs have been reported to express the
integrin subunits a-2,-5,-6,-v and b1,-3,-5 (Braam et al., 2008;
Evseenko et al., 2009; Meng et al., 2010b; Xu et al., 2001) . Func-
tionally, the a6b1 integrin has been defined as a laminin receptor
in hESC, the aVb5 and aVb3 integrins have been identified as
vitronectin receptors, and the a5b1 receptor shown to be a
receptor for fibronectin (Braam et al., 2008; Meng et al., 2010b).
The first report of purified extracellular matrix components in
a defined culture system used a combination of fibronectin, lam-
inin, collagen IV, and vitronectin (Ludwig and Thomson, 2007).
These proteins, purified from natural sources, may contain
various contaminants and generally are not xeno free. Recombi-
nant laminins 332, 511, and 111 were shown to support hESC
maintenance for up to ten passages under defined conditions
(Miyazaki et al., 2008). However, in one study of hESC establish-
ment from explanted blastocysts, it was necessary to combine
a laminin substrate with the use of a feeder cell layer to derive
cell lines (Fletcher et al., 2006). Vitronectin was identified some
years ago as a key attachment factor for pluripotent human
embryonal carcinoma cells (Cooper and Pera, 1988). More
recently, three groups have reported maintenance of hESCs or
human iPSCs in defined conditions on natural or recombinant
vitronectin (Braam et al., 2008; Manton et al., 2010; Rowland526 Cell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc.et al., 2009). One study has employed short peptide ligands for
the aVb3 a6b1 and a2b1 integrins to support hESC adhesion
and growth (Meng et al., 2010b). The peptides were only able
to support hESC maintenance for short periods, which suggests
that the full-length integrin ligands might contain other domains
that are important for longer-term propagation of hESCs. One
study showed that laminin 511 and nidogen together enabled re-
assembly of single hESCs into clumps of cells (Evseenko et al.,
2009). Although the authors of this study focused on embryoid
body formation, it is possible that reaggregation and adhesion
mediated by these factors would enable survival of hESCs after
dissociation.
In addition to these extracellular matrix molecules, hyaluronan
is a candidate factor for promotion of hESC survival. Hylaruronan
may be particularly relevant to hESC derivation because of its
presence in the female reproductive tract and its known roles
in early embryo growth. hESC express the hyaluronan receptor
RHAMM on their surface (Choudhary et al., 2007). Knockdown
of this receptor resulted in death and differentiation. One report
has described long-term maintenance of hESCs in hyaluronan
containing hydrogels, although the study was carried out in the
presence of conditioned medium from mouse embryo fibro-
blasts (Gerecht et al., 2007).
Cryopreservation
In general, the recovery of hESCs after cryopreservation is very
low after use of conventional slow cooling and rapid thawing
protocols widely employed for cultured cells (cryopreservation
medium containing 5%–10% DMSO and culture medium sup-
plemented with serum or serum replacement and freezing at
1C/min) (Fujioka et al., 2004; Reubinoff et al., 2001). Several
groups reported marked improvement in cell recovery by using
vitrification in straws or vials (Fujioka et al., 2004; Hunt and
Timmons, 2007; Reubinoff et al., 2001; Richards et al., 2004).
Given that these vitrification media consist of simple culture
medium and chemical regents only, they provide a means to
cryopreserve cells without animal components. However, these
vitrification protocols often require contact with liquid nitrogen,
posing contamination risks. There are several reports demon-
strating liquid nitrogen contact-free cryopreservation with
controlled cooling systems (Lee et al., 2010; Morris et al.,
2006; Ware and Baran, 2007). In addition, there are several
reports of methods to enhance survival of hESCs after cryopres-
ervation, such as the use of ROCK inhibitor (Li et al., 2009;
Martin-Iban˜ez et al., 2008), caspase inhibitors (Heng et al.,
2007), or microcarriers (Nie et al., 2009). In general, for cryopres-
ervation, hESC colonies need to be dissociated into clumps, just
as in routine passage, and concentrated to high density for
freezing. Closed straws or vials should be used for freezing,
and the vials or straws should be stored in either ultra-low
temperature freezer (150C) or vapor phase of the liquid
nitrogen tank.
Characterization
Standard methods for the characterization of hESC lines typi-
cally include cell-surface marker profiling, gene expression anal-
ysis, and biological assay of differentiation potential, as well as
examination of genetic integrity. The International Stem Cell
Initiative study of 59 cell lines from 17 laboratories established
a panel of cell-surface markers and pluripotency genes that
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lines (Adewumi et al., 2007). Flow cytometry using surface
markers and some of the key pluripotency transcription factors
yields quantitative information about the proportion of cells in
the culture that are positive for these indicators and is an impor-
tant addition to immunofluorescence, which defines cellular
localization of the markers. Likewise, quantitative RT-PCR
(qRT-PCR) should be employed for measuring pluripotency
markers and comparing them with established hESC cultures.
These parameters should be examined at early passage levels
and then at regular intervals.
Characterization of cell lines should include in vitro tests of
differentiation potential. The most commonly used paradigm is
embryoid body formation, with assessment of gene expression
in differentiated cells in the embryoid body or in adherent
cultures derived from it, by immunoflourescence and qRT-
PCR, for lineage-specific markers representative of the three
embryonic germ layers. The reaggregation technique (Ng et al.,
2005) provides for uniform input of cell numbers and avoids
heterogeneity that results from incorporating only selected
regions of colonies into the embryoid body.
The advent and widespread adoption of reprogramming tech-
nology for the derivation of pluripotent cell lines has engendered
a certain amount of debate over the vexed issue of how best to
evaluate pluripotency of cultured human cells (Ellis et al., 2009;
Maherali and Hochedlinger, 2008). The increasing availability of
robust protocols with quantitative endpoints for the neural,
mesodermal, and endodermal differentiation of hESC has led
some to suggest that a panel of such assays could supplant
the need for in vivo teratoma assays. The International Stem
Cell Initiative is convening a series of expert discussion groups
to assess currently available assays and make recommenda-
tions concerning their use.
In the absence of an agreed and proven set of surrogate
in vitro assays, the gold standard for pluripotency in the human
is the formation of teratomas in immunodeprived animals (Przy-
borski, 2005). Protocols for formation of teratomas and their
histological assessment have been published (Gertow et al.,
2007), but they may not always be followed and/or reported in
detail (Mu¨ller et al., 2010). Some groups have combined stan-
dard histological examination with immunochemistry to validate
the human origin of various differentiated tissues in the graft and
to better define the cell lineages represented. However, quanti-
tative assessment of differentiation, and thus definitive evalua-
tion of the ability to give rise to a wide variety of tissue lineages,
remains problematic with this assay. Recent studies have sug-
gested that certain sites and modes of injection might provide
improved yields of tumors (Cooke et al., 2006; Prokhorova
et al., 2008). It is important to remember that in vivo teratoma
formation can provide information not only about differentiation
potential but also about the propensity of cell lines to formmalig-
nant growths (teratocarcinomas) (Blum and Benvenisty, 2008;
Przyborski, 2005). hESCs with a normal karyotype generally
give rise only to teratomas, which do not contain undifferentiated
cells. By contrast, chromosomally abnormal cells, or hESC lines
with small genetic lesions, can yield teratocarcinomas that
contain undifferentiated cells resembling embyonal carcinoma
cells. The presence of undifferentiated cells within a teratoma
is thus a cause for concern.Genetic stability of hESC cell lines is routinely assessed by G-
banded karyotype or, less frequently, spectral karyotyping, at
regular intervals during the development and growth of cell lines
in vitro. More recently, it has become apparent that hESCs can
acquire submicroscopic genetic alterations, including small
amplifications and deletions, that are not detected by karyotype
analysis. It appears that there are hotpsots for such changes
(Na¨rva¨ et al., 2010) and that small changes may be associated
with alterations in cell behavior such as reduced growth factor
requirements, reduced ability to undergo differentiation, and
formation of teratocarcinomas (Werbowetski-Ogilvie et al.,
2009). In one recent study, copy-number variants (CNVs) were
reported to occur frequently in regions containing genes associ-
ated with cancer, but the biological significance of this observa-
tion remains unclear (Na¨rva¨ et al., 2010). Assessment of CNV is
thus becoming more important to the assessment of genetic
integrity of cell lines. None of the current methodologies has ad-
dressed the possibility that hESCs may acquire point mutations
in oncogenes or tumor suppressor genes. As costs of genomic
sequencing decline this may become a realistic option. Preser-
vation of DNA from the blastocyst at hESC derivation would
enable unambiguous determination of whether CNVs are consti-
tutional or acquired during culture.Conclusions
Our understanding of the basis of the extrinsic regulation of plu-
ripotency in hESC (Pera and Tam, 2010) has progressed
considerably and this knowledge has been put to practical im-
plementation in the design of new culture systems. There is
now a variety of technological options for workers wishing to
derive new hESC lines. Nevertheless significant challenges to
the field remain. Among these are the development of defined
culture systems that function robustly in hESC derivation, the
development of defined extracellular matrix components for
support of hESC cultures, the improvement of single-cell survival
of hESCs, and the definition of conditions that provide for long-
term genetic and epigenetic stability. In the areas of hESC char-
acterization, the establishment of a standard panel of in vitro
assays for the assessment of pluripotency should be a priority
for the field. Finally, the cost of many defined culture systems
is a major roadblock to their wider use in expansion of hESC
cultures. It can be anticipated that given the current pace of
human pluripotent stem cell research, platforms that address
these challenges will emerge and come into widespread use
within the next few years.ACKNOWLEDGMENTS
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